Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365223 | 0.95 | ESR2 (0.63) | NR1H2ESR2GPR119HDAC1HDAC6 | |
| SCHEMBL13213329 | 0.90 | NR1H2 (0.66) | NR1H2ESR2GPR119HDAC1HDAC6 | |
| SCHEMBL30301704 | 0.85 | ESR2 (0.67) | NR1H2ESR2GPR119HDAC1HDAC6 | |
| SCHEMBL30368378 | 0.85 | ESR2 (0.67) | NR1H2ESR2GPR119HDAC1HDAC6 | |
| SCHEMBL29589913 | 0.83 | NR1H2 (0.67) | NR1H2ESR2HDAC1HDAC6MAPK1 | |
| SCHEMBL2277894 | 0.83 | NR1H2 (0.67) | NR1H2ESR2HDAC1HDAC6MAPK1 | |
| SCHEMBL29373737 | 0.83 | NR1H2 (0.70) | NR1H2ESR2HDAC1HDAC6MAPK1 | |
| SCHEMBL622590 | 0.83 | NR1H2 (0.70) | NR1H2ESR2HDAC1HDAC6MAPK1 | |
| SCHEMBL14101201 | 0.83 | ESR1 (0.58) | NR1H2ESR2HDAC6MAPK1HDAC8 | |
| SCHEMBL9257641 | 0.82 | NR1H2 (0.73) | NR1H2ESR2GPR119HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| EP-1945222-B1 | PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer Pharma AG (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-1501803-B1 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1945222-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer HealthCare AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | IGF1R, FGFR1, IGFBP1 | NR1H2 2731/4885ESR2 1232/4885GPR119 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.